• Compliance and Connections

    The 3rd Annual Council of Pharmacy Executives and Suppliers (CPES) Meeting is taking place October 3-4 in Franklin, TN. Members of the RxStrategies team will be in attendance, making connections with hospital pharmacy leaders from across the nation while discussing thelatest trends impacting the pharmacy industry and strategies to maintain program compliance. The following team members… Read more »

  • Proud Sponsor of APHCA’s Annual Conference

    RxStrategies is a proud Platinum Presenting Sponsor of Alabama Primary Health Care Association’s (APHCA) 33rd Annual Conference and Trade Show. October 2-4 in Orange Beach, AL, members, partners and collaborators will join together to network and gain insight into leadership, management and compliance strategies. Visit booth #1 at the conference to discuss intuitive 340B solutions with… Read more »

  • Clinical Insights: August 30, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug… Read more »

  • Intuitive Contract Pharmacy Management through Advanced Reporting and Analytics

    RxStrategies emphasizes a conservative approach to 340B contract pharmacy administration while maximizing program results. Our simple, all-inclusive fee ensures more of the 340B savings remain with the Covered Entity (CE). In addition, our audit-proven eligibility matching algorithm drives matches to qualify each individual transaction. Our 340B Contract Pharmacy Solution: Intuitive, Cloud-Based Platform: Provides unprecedented insights into… Read more »

  • Celebrating National Health Center Week!

    According to NACHC, health centers currently serve 27 million patients. This year, National Health Center Week will be recognized on August 12-18. Our team at RxStrategies is appreciative of the many health centers dedicated to providing affordable quality care to their communities. We are honored to be able to support your mission and vision by… Read more »

  • Let’s Connect at the 2018 NACHC CHI & EXPO!

    In just a couple weeks, RxStrategies’ Rhodie Smith and Justin Rolling will attend the National Association of Community Health Centers’ 2018 Community Health Institute (CHI) & EXPO! Taking place August 24-28, 2018 in Orlando, FL, this gathering is the largest of its kind, offering opportunities for health center clinicians, executives, consumer board members and other… Read more »

  • Clinical Insights: August 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Mulpleta® (lusutrombopag) – July 31, 2018 – The Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are… Read more »

  • 340B Insider – July 2018

    Welcome to the July edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   UPDATES FROM THE 340B COALITION SUMMER CONFERENCE It was great to connect with so many of our clients and industry leaders during the 340B Coalition Summer Conference in Washington D.C. In addition to being a… Read more »

  • Clinical Insights: July 19, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymtuzaTM (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) – July 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration… Read more »